NCT02101281View on ClinicalTrials.gov

Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 20, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Dry Eye Syndrome
Interventions
DRUG

rhNGF 20 µg/mL

1 drop for each eye, twice daily for 28 day

DRUG

rhNGF 4 µg/mL

1 drop each eye, twice daily for 28 day

Trial Locations (1)

1090

Department of Clinical Pharmacology, Vienna

Sponsors

Collaborators (1)

Cross Research S.A.
All Listed Sponsors
collaborator

Cross Research S.A.

INDUSTRY

lead

Dompé Farmaceutici S.p.A

INDUSTRY